Rifaximin 550 milligram
ApprovedSmall molecule
Rifaximin 550 milligram is one of 58 small molecule programs targeting Encephalopathy. It is currently in Approved.
2
Indications
2
Total Trials
1
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
135 competitors in Encephalopathy
#DrugCompanyPhaseTrials
1Xifaxan
SSalix
Phase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Alinia
RRomark Laboratories L.C.
Phase 3
PROCRIT
WWim Janssens
Phase 3
Cafcit
KKaken Pharmaceutical
Phase 3
Aranesp
AmgenPhase 2
Fludara
SanofiPhase 2
Yescarta
GileadPhase 2
MS Contin
Merck & Co.Phase 2
Fludara
SanofiPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatorenal Syndrome1 trial
Encephalopathy1 trial
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Recruiting·—·Phase 4·NCT04073290·238 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Rifaximin 550 milligram. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- SSamar Atef Sebaweh Mohammed